In particular, MUC16, also known as CA-125, merits additional investigation given its emergence as a distinctive grading feature, since current literature supports this marker in ovarian cancer with clinical use; however, it is identified as mutated in only a relatively small percentage of gliomas [37]. This evidence concerns the gene MUC16 and central nervous system cancer.